-
公开(公告)号：US07557108B2
公开(公告)日：2009-07-07
申请号：US12018284
申请日：2008-01-23
申请人： Matthias Nettekoven , Olivier Roche
发明人： Matthias Nettekoven , Olivier Roche
IPC分类号： A61K31/496 , C07D209/08 , C07D235/06
CPC分类号： C07D209/08 , C07D235/06
摘要： The present invention relates to compounds of formula I wherein one of R1 and R2 is hydrogen and the other one is and wherein A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译： 本发明涉及式I化合物，其中R 1和R 2之一是氢，另一个是且其中A和R 1至R 4如说明书和权利要求中所定义，及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号：US07514433B2
公开(公告)日：2009-04-07
申请号：US11880083
申请日：2007-07-19
申请人： Matthias Nettekoven , Olivier Roche
发明人： Matthias Nettekoven , Olivier Roche
IPC分类号： A61K31/5377 , A61K31/496 , C07D401/14 , C07D413/14
CPC分类号： C07D403/06 , C07D401/14 , C07D413/14
摘要： The present invention relates to the compounds of formula I: wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译： 本发明涉及式I化合物：其中R 1至R 4如说明书和权利要求书中所定义，及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号：US20080249125A1
公开(公告)日：2008-10-09
申请号：US12056324
申请日：2008-03-27
申请人： Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
发明人： Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
IPC分类号： A61K31/437 , C07D471/02 , C07D513/02 , A61K31/4365 , A61K31/4375 , A61P25/00
CPC分类号： C07D471/04 , C07D495/04
摘要： The present invention relates to compounds of formula wherein R1, R2, R3, and R4 are as defined herein and hetaryl is a one or two ring-membered heteroaromatic ring system, connected to the carbon atoms of the piperidine group selected from the group consisting of or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders in which orexin pathways are involved, like sleep disorders.
摘要翻译： 本发明涉及下式的化合物其中R 1，R 2，R 3和R 4是 如本文所定义，杂芳基是与哌啶基的碳原子连接的一个或两个环 - 元杂芳族环系统，所述哌啶基团选自由药学上合适的酸加成盐，光学纯对映异构体，外消旋体或非对映体混合物组成的组。 这些化合物是食欲素受体拮抗剂，并且可用于治疗涉及食欲素途径的疾病，例如睡眠障碍。
-
公开(公告)号：US20080188486A1
公开(公告)日：2008-08-07
申请号：US12018284
申请日：2008-01-23
申请人： Matthias Nettekoven , Olivier Roche
发明人： Matthias Nettekoven , Olivier Roche
IPC分类号： A61K31/496 , C07D295/00 , A61P3/04
CPC分类号： C07D209/08 , C07D235/06
摘要： The present invention relates to compounds of formula I wherein one of R1 and R2 is hydrogen and the other one is and wherein A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译： 本发明涉及式I化合物，其中R 1和R 2之一是氢，另一个是且其中A和R 1， R 4和R 4如在说明书和权利要求书中所定义，及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
![4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives](/abs-image/US/2008/06/19/US20080146559A1/abs.jpg.150x150.jpg)
公开(公告)号：US20080146559A1
公开(公告)日：2008-06-19
申请号：US11942755
申请日：2007-11-20
申请人： Li Chen , Wayne Wen Lai , Matthias Nettekoven , Olivier Roche , Deye Zheng
发明人： Li Chen , Wayne Wen Lai , Matthias Nettekoven , Olivier Roche , Deye Zheng
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/5377 , C07D413/14 , A61K31/497 , C07D401/14
CPC分类号： C07D495/04
摘要： The present invention relates to compounds of formula I wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译： 本发明涉及式I化合物，其中R 1和R 2如在说明书和权利要求书中所定义，及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号：US20060135528A1
公开(公告)日：2006-06-22
申请号：US11301052
申请日：2005-12-12
IPC分类号： A61K31/496 , C07D403/14
CPC分类号： C07D213/74 , C07D213/75 , C07D213/76
摘要： The present invention relates to compounds of formula I wherein R1, R2, X, Y, Z and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
摘要翻译： 本发明涉及其中R 1，R 2，X，Y，Z和m如说明书和权利要求书中所定义的式I化合物和药学上可接受的盐 以及包含这些化合物的药物组合物及其制备方法。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。
-
公开(公告)号：US08207220B2
公开(公告)日：2012-06-26
申请号：US12958440
申请日：2010-12-02
IPC分类号： A61K31/38
CPC分类号： C07D413/12 , C07D403/12 , C07D413/14 , C07D417/12
摘要： The present invention is concerned with novel sulfonamides of formula I wherein R1, R2, Ar, Hetaryl, m and n are as described in the description and claims. The compounds are orexin receptor antagonists, useful in the treatment of disorders, in which orexin pathways are involved.
摘要翻译： 本发明涉及式I的新型磺酰胺，其中R 1，R 2，Ar，杂芳基，m和n如说明书和权利要求中所述。 这些化合物是食欲素受体拮抗剂，可用于治疗食欲素途径参与的病症。
-
公开(公告)号：US07829563B2
公开(公告)日：2010-11-09
申请号：US12037975
申请日：2008-02-27
申请人： Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
发明人： Luca Gobbi , Henner Knust , Parichehr Malherbe , Matthias Nettekoven , Emmanuel Pinard , Olivier Roche , Mark Rogers-Evans
IPC分类号： A61K31/50 , A61K31/501 , A61K31/497 , A01N43/54 , C07D239/42 , C07D401/04 , A01N43/40 , A61K31/435 , A01N43/78 , A61K31/425 , A01N43/50 , A61K31/415 , A01N43/56 , A01N43/08 , A61K31/34 , C07D279/00 , C07D285/00 , C07D401/00 , C07D421/00 , C07D419/00 , C07D277/04 , C07D277/08 , C07D409/00 , C07D335/00 , C07D333/02 , C07D321/00 , C07D307/00 , C07D317/00 , C07D323/02
CPC分类号： C07D213/36 , A61K9/2018 , A61K9/4858 , C07C237/20 , C07C2601/02 , C07C2601/04
摘要： The present invention relates to compounds of formula I wherein Ar1, Ar2, Ar3, n, and R1 to R8 are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved, like sleep disorders.
摘要翻译： 本发明涉及式I化合物，其中Ar1，Ar2，Ar3，n和R1至R8如本文所定义，以及其药学上合适的酸加成盐，光学纯对映异构体，外消旋体或非对映体混合物。 这些化合物是食欲肽受体拮抗剂，并且可用于治疗涉及食欲素途径的疾病，例如睡眠障碍。
-
公开(公告)号：US20100029664A1
公开(公告)日：2010-02-04
申请号：US12506302
申请日：2009-07-21
IPC分类号： A61K31/498 , C07D413/12 , A61K31/423 , C07D417/12 , A61K31/428 , C07D413/14 , C07D417/14 , C07D403/12
CPC分类号： C07D413/12 , C07D403/12 , C07D413/14 , C07D417/12
摘要： The present invention is concerned with novel sulfonamides of formula I wherein R1, R2, Ar, Hetaryl, m and n are as described in the description and claims. The compounds are orexin receptor antagonists, useful in the treatment of disorders, in which orexin pathways are involved.
摘要翻译： 本发明涉及式I的新型磺酰胺，其中R 1，R 2，Ar，杂芳基，m和n如说明书和权利要求中所述。 这些化合物是食欲素受体拮抗剂，可用于治疗食欲素途径参与的病症。
-
公开(公告)号：US20090163485A1
公开(公告)日：2009-06-25
申请号：US12334559
申请日：2008-12-15
IPC分类号： A61K31/5365 , C07D263/54 , A61K31/421 , C07D241/36 , A61K31/498 , C07D417/02 , A61K31/428 , C07D221/00 , A61K31/4245 , A61P25/00 , A61K31/501 , C07D403/02 , A61K31/505 , C07D239/24 , C07D271/06 , A61K31/454 , C07D215/38 , A61K31/4709 , C07D239/72 , A61K31/517 , C07D265/12
CPC分类号： C07D413/12 , C07D401/12 , C07D409/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D498/04
摘要： The present invention relates to compounds of formula wherein Ar, Het, R1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.
摘要翻译： 本发明涉及下式的化合物其中Ar，Het，R 1和n如本文所定义，并且与药学上合适的酸加成盐，光学纯对映异构体，外消旋物或非对映体混合物相关。 式I化合物是食欲蛋白受体拮抗剂，可用于治疗睡眠呼吸暂停，发作性睡病，失眠，睡眠不正，夜间综合征，昼夜节律障碍和与神经疾病相关的睡眠障碍。
-
-
-
-
-
-
-
-
-
搜索结果
127 条记录 (耗时 0.06 秒)
